Poseida Therapeutics Inc
NASDAQ:PSTX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2
4.13
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PSTX stock under the Base Case scenario is 0.87 USD. Compared to the current market price of 2.73 USD, Poseida Therapeutics Inc is Overvalued by 68%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Poseida Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PSTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Poseida Therapeutics Inc
Balance Sheet Decomposition
Poseida Therapeutics Inc
Current Assets | 250.7m |
Cash & Short-Term Investments | 230.9m |
Receivables | 14.7m |
Other Current Assets | 5.1m |
Non-Current Assets | 42.9m |
PP&E | 36.4m |
Intangibles | 5.5m |
Other Non-Current Assets | 905k |
Current Liabilities | 78.3m |
Accounts Payable | 5.2m |
Accrued Liabilities | 31.5m |
Other Current Liabilities | 41.6m |
Non-Current Liabilities | 128.1m |
Long-Term Debt | 58.9m |
Other Non-Current Liabilities | 69.2m |
Earnings Waterfall
Poseida Therapeutics Inc
Revenue
|
150.9m
USD
|
Operating Expenses
|
-213.4m
USD
|
Operating Income
|
-62.5m
USD
|
Other Expenses
|
1.7m
USD
|
Net Income
|
-60.8m
USD
|
Free Cash Flow Analysis
Poseida Therapeutics Inc
USD | |
Free Cash Flow | USD |
PSTX Profitability Score
Profitability Due Diligence
Poseida Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Poseida Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
PSTX Solvency Score
Solvency Due Diligence
Poseida Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Poseida Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PSTX Price Targets Summary
Poseida Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for PSTX is 14.28 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.
Dividends
Current shareholder yield for PSTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PSTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 263 full-time employees. The company went IPO on 2020-07-10. The firm is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. The company is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The firm's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).
Contact
IPO
Employees
Officers
The intrinsic value of one PSTX stock under the Base Case scenario is 0.87 USD.
Compared to the current market price of 2.73 USD, Poseida Therapeutics Inc is Overvalued by 68%.